


Divisional of U.S.S.N. 09/603,713  
Filed: April 30, 2001  
**PRELIMINARY AMENDMENT**  
Express Mail Label No.: EL 709 418 840 US  
Date of Deposit: April 30, 2001

correctly at the time the application was filed. These symbols have been inserted into Table 2.

No new subject matter has been added.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'P. L. Pabst', is written over a horizontal line.

Patrea L. Pabst  
Reg. No. 31,284

Date: April 30, 2001


ARNALL, GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8794  
(404) 873-8795 (fax)

Divisional of U.S.S.N. 09/603,713  
Filed: April 30, 2001  
**PRELIMINARY AMENDMENT**  
Express Mail Label No.: EL 709 418 840 US  
Date of Deposit: April 30, 2001

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10**

I hereby certify that this paper and any documents referred to as attached or enclosed are being deposited with the United States Postal Service on this date, April 30, 2001, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Mailing Label Number EL 709 418 840 US addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: April 30, 2001

  
Aisha Wyatt

*Claims As Pending Upon Entry of Preliminary Amendment*

21. A method for treating a patient to decrease the likelihood of developing or the progression of Alzheimer's disease comprising administering to the individual an effective amount of an inhibitor of memapsin 2 having an  $K_i$  of less than or equal to  $10^{-7}M$  or which binds to crystallized enzyme characterized by the parameters in Table 2 when bound to OM-99-2.

22. The method of claim 21 wherein the inhibitor is administered orally.

23. The method of claim 21 wherein the inhibitor blocks cleavage of APP.

24. The method of claim 21 wherein the inhibitor is modeled using a computer program based on the crystallization coordinates of memapsin 2.

25. The method of claim 21 wherein the inhibitor is modeled using a computer program based on the parameters for memapsin shown in Table 2.

26. The method of claim 21 comprising creating a data base of data obtained by modeling more than one inhibitor based on the crystallization coordinates of memapsin 2 or parameters of Table 2.